Increased Sodium Intake Is Not Associated with MS Activity or Progression in BENEFIT (S37.002)

Conclusions: Our results, based on multiple assessments of sodium excretion over 5 years and standardized clinical and MRI follow-up, suggest that salt intake does not influence MS disease course or activity.Disclosure: Dr. Fitzgerald has nothing to disclose. Dr. Munger has nothing to disclose. Dr. Freedman has received research support from Bayer Healthcare and Genzyme. Dr. Hartung has received personal compensation for activities with from Bayer, Biogen, GeNeuro, Genzyme as speaker, committee member, consultant. Dr. Montalban has received personal compensation for activities with Actelion, Almirall, Bayer Pharmaceuticals, Biogen Idec, Genzyme Corporation, Merck & Co., Inc., NeuroTex, Novartis, Octopharma, Receptos, and Roche Diagnostics Corporation as a speaker. Dr. Edan has nothing to disclose. Dr. Barkhof has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Genzyme, Janssen Research, Merck Serono, Novartis, Roche, Sanofi, Synthon BV, and Teva as a consultant. Dr. Radue has received research support from Actelion, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, and Sanofi. Dr. Kappos's institution (University Hospital Basel) has received royalty payments from Neurostatus Systems GmbH. Dr. Suarez has received personal compensation for activities with Bayer Pharma AG/Bayer HealthCare Pharmaceuticals as an employee. Dr. Ascherio has received personal compensation for activities with Almirall, Bayer HealthCareRoche, Sanof...
Source: Neurology - Category: Neurology Authors: Tags: Risk Factors for Multiple Sclerosis Source Type: research